retatrutide eli lilly phase 2 results Lilly's triple agonist achieves 16.8% weight loss in 3 trial retatrutide weight loss phase 2

Exercise and injection site selection Exercise increases blood flow to working muscles and surrounding tissue

Tirzepatide at its highest approved dose of 15mg produced approximately 22% weight loss, but over a longer 72-week trial period

A warning about compounded semaglutide: the FDA does not approve compounded versions of GLP-1s, and the agency has issued specific warnings about safety risks in 2026

The glucagon receptor component is hypothesised to increase energy expenditure and promote fat breakdown (lipolysis), potentially offering additional weight loss benefits

Statins help lower LDL cholesterol, which reduces the risk of stroke or death from a heart attack, Dr

Paolisso G, Gambardella A, Tagliamonte MR, Saccomanno F, Salvatore T, Gualdiero P, DOnofrio MV, Howard BV